Viatris Japan, Australia and New Zealand Segment — Cost of Sales decreased by 12.4% to $174.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.2%, from $176.50M to $174.40M. This is a positive signal — lower values indicate better performance for this metric.
A lower cost of sales relative to revenue indicates higher gross margins and better operational efficiency.
This metric includes the direct costs attributable to the production and distribution of pharmaceutical products sold wi...
Standard cost of goods sold metric for regional segments in the pharmaceutical industry.
vtrs_segment_japan_australia_and_new_zealand_segment_cost_of_sales| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $189.40M | $207.30M | $202.50M | $176.50M | $181.70M | $199.20M | $174.40M |
| QoQ Change | — | +9.5% | -2.3% | -12.8% | +2.9% | +9.6% | -12.4% |
| YoY Change | — | — | — | -6.8% | -12.3% | -1.6% | -1.2% |